Published Date:2022-11-09 Original Link:https://www.onenessbio.com/en/news_detail182_1.htm No 2 Date of announcement 2022/11/09 Time of announcement 16:45:58 Subject Annouce the change of the corporate governance officer. To which item it meets paragraph 8 Date of events 2022/11/09 Statement Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate...Read More
Published Date:2022-11-09 Original Link:https://www.onenessbio.com/en/news_detail183_1.htm No 3 Date of announcement 2022/11/09 Time of announcement 16:48:49 Subject The Board of Directors of Oneness has approved a donation to Teh-Tzer Study Group for Human Medical Research Foundation. To which item it meets paragraph 43 Date of events 2022/11/09 Statement Date of occurrence of the event:2022/11/09 Reason for the...Read More
Published Date:2022-11-09 Original Link:https://www.onenessbio.com/en/news_detail181_1.htm No 1 Date of announcement 2022/11/09 Time of announcement 16:11:18 Subject The Company’s 2022Q3 consolidated financial statements have been approved by the Board of Directors To which item it meets paragraph 31 Date of events 2022/11/09 Statement Date of the board of directors submitted or approved:2022/11/09 Date of the audit committee...Read More
Published Date:2022-10-27 Original Link:https://www.onenessbio.com/en/news_detail180_1.htm No 1 Date of announcement 2022/10/27 Time of announcement 17:02:31 Subject Oneness Biotech Co., Ltd. receives Israeli, Mexican and Hong Kong patents on the producing recombinant glycoproteins with modified glycosylation. To which item it meets paragraph 53 Date of events 2022/10/27 Statement Date of occurrence of the event: 111/10/27 Company name:...Read More
Date 2022/09/30 Location Online Presentation Download Download Chinese Version Download English Version Video Recording (English interpretation) Note N/ARead More
Published Date:2022-09-28 Original Link:https://www.onenessbio.com/en/news_detail179_1.htm No 1 Date of announcement 2022/09/28 Time of announcement 19:20:15 Subject Fespixon’s clinical meaningfulness as a macrophage-regulation new drug compared with other DFU treatments has been reviewed and published in Pharmaceutics. To which item it meets paragraph 53 Date of events 2022/09/28 Statement Date of occurrence of the event:2022/09/28 Company name:ONENESS...Read More
Published Date:2022-09-23 Original Link:https://www.onenessbio.com/en/news_detail178_1.htm No 2 Date of announcement 2022/09/23 Time of announcement 17:37:19 Subject Oneness announces the information about the investor’s conference of 2022 Q3. To which item it meets paragraph 12 Date of events 2022/09/30 Statement Date of institutional investor conference:2022/09/30 Time of institutional investor conference:15:00 (GMT+8) Location of institutional investor conference:Online Investor...Read More
Published Date:2022-09-23 Original Link:https://www.onenessbio.com/en/news_detail177_1.htm No 1 Date of announcement 2022/09/23 Time of announcement 17:14:21 Subject SNS812, a broad-spectrum siRNA co-developed by Oneness and Microbio (Shanghai) to treat SARS-CoV-2 infection, was greenlighted by FDA to proceed with a Ph1 study To which item it meets paragraph 10 Date of events 2022/09/23 Statement Product:SNS812, a broad-spectrum siRNA...Read More
Published Date:2022-08-26 Original Link:https://www.onenessbio.com/en/news_detail176_2.htm No 1 Date of announcement 2022/08/26 Time of announcement 15:12:12 Subject The trading of Oneness securities in centralized securities exchange market follows Announcement or Notice of Attention to Trading Information To which item it meets paragraph 53 Date of events 2022/08/26 Statement Date of occurrence of the event:2022/08/26 Cause of occurrence:Proceeded...Read More
